Last $1.26 USD
Change Today +0.02 / 1.61%
Volume 449.7K
ABIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

arca biopharma inc (ABIO) Snapshot

Open
$1.25
Previous Close
$1.24
Day High
$1.36
Day Low
$1.20
52 Week High
01/8/14 - $2.54
52 Week Low
09/29/14 - $1.17
Market Cap
26.5M
Average Volume 10 Days
143.1K
EPS TTM
$-0.59
Shares Outstanding
21.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARCA BIOPHARMA INC (ABIO)

Related News

No related news articles were found.

arca biopharma inc (ABIO) Related Businessweek News

No Related Businessweek News Found

arca biopharma inc (ABIO) Details

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

14 Employees
Last Reported Date: 03/21/14

arca biopharma inc (ABIO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $389.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $338.8K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $323.6K
Compensation as of Fiscal Year 2013.

arca biopharma inc (ABIO) Key Developments

ARCA biopharma, Inc. Announces Health Canada Acceptance of GENETIC-AF Clinical Trial Application

ARCA biopharma, Inc. announced that the company's Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in the fourth quarter of 2014. ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the United States. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation. AF is a disorder in which the normally regular and coordinated contraction pattern of the heart's two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF) patients. GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients. ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial in approximately 200 patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.

ARCA biopharma, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM

ARCA biopharma, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

ARCA biopharma, Inc. Elects Robert E. Conway as Chairman of the Board of Directors

ARCA biopharma, Inc. announced that Robert E. Conway has been elected Chairman of the company's Board of Directors. He serves on the Audit and Compensation Committees of the Board of Directors. Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. Mr. Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABIO:US $1.26 USD +0.02

ABIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABIO.
View Industry Companies
 

Industry Analysis

ABIO

Industry Average

Valuation ABIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.